CANCER IMMUNOTHERAPY LEADER JOINS IMMUNEERING’S EXECUTIVE TEAM TO APPLY THE COMPANY’S DISEASE CANCELLING TECHNOLOGY TO IMMUNO-ONCOLOGY CAMBRIDGE, Mass. – Jan. 9, 2020 – Immuneering Corporation today announced an addition…
Read More
INDUSTRY VETERAN JOINS EXECUTIVE TEAM AS IMMUNEERING ADVANCES RAPIDLY GROWING PIPELINE OF CANCER MEDICINES DRIVEN BY DISEASE CANCELLING TECHNOLOGY CAMBRIDGE, Mass. – Dec. 19, 2019 – Immuneering Corporation today…
FUNDING TO ADVANCE RAPIDLY-GROWING PIPELINE OF CANCER MEDICINES DRIVEN BY DISEASE CANCELLING TECHNOLOGY AND EXPAND SERVICES BUSINESS CAMBRIDGE, Mass. – Dec. 16, 2019 – Immuneering Corporation today announced the…
Immuneering to Present at the 12th International Conference on Cachexia, Sarcopenia & Muscle Wasting
CAMBRIDGE, Mass., Dec. 04, 2019 (GLOBE NEWSWIRE) — Immuneering today announced the company’s participation in the 12th International Conference on Cachexia, Sarcopenia & Muscle Wasting taking place in Berlin, Dec. 6-8,…
Excerpt from Chapter 1 – Computational Toxicology Promotes Regulatory Science: New tools have become available to researchers and regulators including genomics, transcriptomics, proteomics, machine learning, artificial intelligence, molecular dynamics, bioinformatics,…
Toxicant screening is only as efficient and effective as the underlying methods. Unfortunately, chemical toxicity screening is predominated by slow, laborious, and costly methods some of which raise ethical concerns….
Reference genome selection is a prerequisite for successful analysis of next generation sequencing (NGS) data. Current practice employs one of the two most recent human reference genome versions: HG19 or…
Endocrine disrupting chemicals (EDCs) mimic natural hormones and disrupt endocrine function. Humans and wildlife are exposed to EDCs might alter endocrine functions through various mechanisms and lead to an adverse…
Endocrine disrupting chemicals (EDCs) mimic natural hormones and disrupt endocrine function. Humans and wildlife are exposed to EDCs might alter endocrine functions through various mechanisms and lead to an adverse…
Hamburg, Germany, and Cambridge, USA, 21 November 2018: Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that it has entered into a research collaboration with Immuneering Corporation…
